02.04.26 -- At JP Morgan 2026, Few Showed Up For U.S. Manufacturing

Join Outsourced Pharma Chief Editor Jeff Buguliskis and our panel of industry experts as they share practical advice, reveal what to look for beyond the surface, and answer your toughest questions about selecting a CDMO partner that can truly deliver. Register for free today!

Designed for scientists and engineers evaluating advanced reactors, this recording delivers practical insights and real-world examples to support safer, more efficient, and adaptable flow chemistry.

As peptide therapeutics continue to establish themselves as a leading technology for treating chronic indications, drug sponsors must identify peptide building block suppliers to secure starting materials.

Explore the key to maintaining and enhancing existing and new partnerships as well as how outsourcing one crucial aspect of bringing products to market can benefit overall supply chain optimization.

The promise of AI is colliding with the harsh reality of data chaos in pharma manufacturing. This article explores why most AI investments fail, and a 5-layer solution.

A biotech with limited experience in the development and manufacture of high potency compounds sought to develop a process for producing a highly potent API used to treat an unmet oncology need.

Although well-established processes, spray drying and hot-melt extrusion can be outperformed in bioavailability, cost-savings, manufacturing speed, environmental impact, and more.

Learn more about defining the spray drying process with an emphasis on specific enhancements to accommodate scale-up to commercial scale equipment of challenging applications or molecules.

Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development.

Choose an experienced CDMO specializing in high-potency softgels and liquids to ensure high-quality products, responsive service, and reliable solutions across complex therapeutic areas.

Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

See how modern filling infrastructure is driving efficiency, enhancing flexibility, and supporting long-term expansion within the injectable manufacturing space.